Simcere and Stanford Partner on Novel IPF Therapy Research
HONG KONG and STANFORD, Calif., June 12, 2026 Simcere Pharmaceutical Group Limited has entered into a strategic research collaboration...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
HONG KONG and STANFORD, Calif., June 12, 2026 Simcere Pharmaceutical Group Limited has entered into a strategic research collaboration...
BASEL, Switzerland, June 12, 2026 Novartis announced new Phase III data at the European Academy of Allergy and Clinical...
BOSTON and SHENZHEN, China, June 10, 2026 XtalPi, a global leader in AI and robotics-driven drug discovery, has announced...
